ID   NCC-ESOS1-C1
AC   CVCL_YD21
DR   cancercelllines; CVCL_YD21
DR   Wikidata; Q95992527
RX   DOI=10.2198/jelectroph.65.1;
RX   PubMed=31625124;
WW   https://en.cellline.jp/product/ncc-esos1-c1/
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Characteristics: Exhibits invasion capability (PubMed=31625124).
CC   Senescence: It is possible that this cell line is not immortal and has a finite life span (personal communication of Kondo T.).
CC   Doubling time: ~40 hours (PubMed=31625124); ~24 hours (DOI=10.2198/jelectroph.65.1).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=31625124).
CC   Derived from site: Metastatic; Forearm, hypodermis; UBERON=UBERON_0002386+UBERON_0002072.
ST   Source(s): PubMed=31625124
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11,13
ST   D16S539: 9,10
ST   D21S11: 29,32
ST   D5S818: 11,12,13
ST   D7S820: 10,12
ST   TH01: 8,9
ST   TPOX: 8
ST   vWA: 14,18
DI   NCIt; C8810; Extraskeletal osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 30-01-24; Version: 10
//
RX   DOI=10.2198/jelectroph.65.1;
RA   Noguchi R., Yoshimatsu Y., Ono T., Sei A., Kondo T.;
RT   "Proteogenomic approach to drug targets in osteosarcomas with
RT   different original sites.";
RL   J. Electroph. 65:1-11(2021).
//
RX   PubMed=31625124; DOI=10.1007/s13577-019-00291-z;
RA   Kito F., Oyama R., Noguchi R., Hattori E., Sakumoto M., Endo M.,
RA   Kobayashi E., Yoshida A., Kawai A., Kondo T.;
RT   "Establishment and characterization of novel patient-derived
RT   extraskeletal osteosarcoma cell line NCC-ESOS1-C1.";
RL   Hum. Cell 33:283-290(2020).
//